2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2015

11:00AM-12:30PM: Abstract Number: 1999

Improvement in Mortality in RA Compared to the General Population – Closing the Mortality Gap

ACR Plenary Session II: Discovery 2015

11:00AM-12:30PM: Abstract Number: 1997

Underuse of Methotrexate (MTX) in the Treatment of Rheumatoid Arthritis (RA) in the United States (US): Results of a Comprehensive Pharmaceutical Claims Analysis

ACR Plenary Session II: Discovery 2015

2:30PM-4:00PM: Abstract Number: 2026

A Novel Technique for Quantifying Synovial Enhancement of Temporomandibular Joints from Mris of Patients with Juvenile Idiopathic Arthritis

Imaging of Rheumatic Diseases II: MRI, PET and CT

2:30PM-4:00PM: Abstract Number: 2055

A Phase III, Randomized, Double-Blind Clinical Study Comparing SB4, an Etanercept Biosimilar, with Etanercept Reference Product (Enbrel®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (52-week Results)

Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy III: Biosimilars

2:30PM-4:00PM: Abstract Number: 2047

A Randomised Double-Blind Placebo-Controlled Trial of Vitamin D Supplementation in Juvenile-Onset Systemic Lupus Erythematosus: Effects on Microarchitecture Measured By HR-pQCT

Pediatric Rheumatology - Clinical and Therapeutic Aspects II: Pediatric Systemic Lupus Erythematosus

2:30PM-4:00PM: Abstract Number: 2056

A Randomized, Double-Blind, Phase III Study Comparing SB2, an Infliximab Biosimilar, to the Infliximab Reference Product (Remicade®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy: 54-Week Results

Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy III: Biosimilars

2:30PM-4:00PM: Abstract Number: 2075

A Unique Naturally-Occurring Regulatory T Cell Subset Associated with Disease Activity in Patients with Systemic Lupus Erythematosus

Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: Modulators of Disease

2:30PM-4:00PM: Abstract Number: 2038

Adalimumab in Patients with Active, Noninfectious Uveitis Using High-Dose Corticosteroids

Miscellaneous Rheumatic and Inflammatory Diseases Oral Session II

2:30PM-4:00PM: Abstract Number: 2010

Adenosine A2A Receptor, but Not A2B Receptor, Deletion Leads to Development of Osteoarthritis (OA) in Mice and Administration of a Liposomal Suspension of Adenosine Prevents/Treats Osteoarthritis in Rats

Biology and Pathology of Bone and Joint: Ostearthritis Pathogenesis

2:30PM-4:00PM: Abstract Number: 2022

Adherence to the Dietary Guidelines for Americans and Risk of Developing Rheumatoid Arthritis in Young and Middle-Aged Women

Epidemiology and Public Health II: RA and Lifestyle Factors

2:30PM-4:00PM: Abstract Number: 2053

Adjustment of Skeletal Muscle Mass Estimates for the Extent of Adiposity Strengthens Relationships with Functional Outcomes in Rheumatoid Arthritis

Rheumatoid Arthritis - Clinical Aspects II: Infection, Malignancy and Other Comorbidites in RA

2:30PM-4:00PM: Abstract Number: 2057

Antibodies to Infliximab in Remicade-Treated Rheumatic Patients Show Identical Reactivity Towards Biosimilars

Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy III: Biosimilars

2:30PM-4:00PM: Abstract Number: 2044

Axonal Dysfunction in Childhood-Onset Systemic Lupus Erythematosus. Association with Neuropsychiatric Manifestations and Disease Activity

Pediatric Rheumatology - Clinical and Therapeutic Aspects II: Pediatric Systemic Lupus Erythematosus

2:30PM-4:00PM: Abstract Number: 2041

Baseline Clinical and Laboratory Features of IgG4-Related Disease: Retrospective Japanese Multicenter Study of 333 Cases

Miscellaneous Rheumatic and Inflammatory Diseases Oral Session II

2:30PM-4:00PM: Abstract Number: 2023

Breastfeeding, Oral Contraceptive and the Risk of Rheumatoid Arthritis: Results from the Swedish Epidemiological Investigation of RA Study

Epidemiology and Public Health II: RA and Lifestyle Factors

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].